SBIR/STTR Research Award
XRpro Technology for the Detection and Evaluation of Carcinogens
Award amount
$200,000Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Icagen, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PHS2010-2
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its novel XRpro(R) technology to extract, concentrate, quantify, and characterize carcinogens from biological samples. This will also identify protein adduct biomarkers that are involved in critical carcinogenic and biotransformation pathways. This project addresses challenges listed in PA-09-187, including the measurement of carcinogens directly, without antibodies, dyes, tags, or radioactive materials. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. This project addresses challenges listed in PA-09-187, including the measurement of carcinogens directly, without antibodies, dyes, tags, or radioactive materials.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis